Crossref
Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?
AME Clinical Trials Review · 2026-06 · 4 · 24-24
DOI: 10.21037/actr-25-107 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Takahiro Karasaki.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Karasaki, T. (2026). Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?. AME Clinical Trials Review, 4, 24-24. https://doi.org/10.21037/actr-25-107
Vancouver
Karasaki T. Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?. AME Clinical Trials Review. 2026;4:24-24. doi:10.21037/actr-25-107
BibTeX
@article{Karasaki2026,
author = {Karasaki, Takahiro},
title = {Neoadjuvant osimertinib: a new standard in resectable EGFR-mutated non-small cell lung cancer?},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {24--24},
doi = {10.21037/actr-25-107}
}
EUVIMED